Cannabigerol (CBG)

Cannabigerol (CBG) is a non-psychoactive cannabinoid that acts as a partial agonist of CB1 and CB2 receptors while modulating TRPM8 and α2-adrenergic receptors. CBG demonstrates neuroprotective, anti-inflammatory, and intraocular pressure-reducing properties through multiple molecular pathways.

Origin & History

Cannabigerol (CBG) is a minor cannabinoid found in the cannabis plant, often extracted from young plants where it is more abundant. It is typically obtained using CO2 extraction methods.

Historical & Cultural Context

CBG was identified in the 1960s but has gained attention recently as research explores its unique benefits compared to other cannabinoids.

Health Benefits

- Supports neuroprotection and brain health by promoting the growth of new brain cells, potentially reducing the risk of neurodegenerative diseases. - May reduce inflammation and pain by inhibiting inflammatory pathways, offering relief for chronic pain sufferers. - Promotes eye health by reducing intraocular pressure, which can help prevent glaucoma. - Enhances mood and mental clarity by interacting with serotonin receptors, leading to improved emotional well-being. - Supports digestive health by modulating gut microbiota, which can improve nutrient absorption and gut function. - Boosts immune system function by enhancing the body's natural defense mechanisms, helping to ward off illnesses. - Promotes skin health by reducing inflammation and promoting collagen production, leading to healthier, more resilient skin.

How It Works

CBG acts as a weak partial agonist of CB1 and CB2 cannabinoid receptors while antagonizing α2-adrenergic receptors and activating TRPM8 channels. It inhibits the reuptake of anandamide and modulates adenosine A2A receptors, contributing to its neuroprotective effects. CBG also interacts with 5-HT1A serotonin receptors and blocks calcium channels, which underlies its anti-inflammatory and analgesic properties.

Scientific Research

Preliminary studies, including in vitro and animal research, suggest potential benefits in neuroprotection and inflammation. Human trials are limited but ongoing.

Clinical Summary

Human clinical research on CBG remains limited, with most evidence derived from preclinical studies and animal models. A small pilot study (n=127) found CBG effective for anxiety, chronic pain, and sleep issues, with 73.9% reporting improved sleep quality. Animal studies demonstrate significant neuroprotective effects in Huntington's disease models and inflammatory bowel disease, with dosages ranging from 1-10 mg/kg showing efficacy. Current evidence is promising but requires larger randomized controlled trials to establish therapeutic dosing and long-term safety profiles.

Nutritional Profile

- Contains cannabinoids that interact with the endocannabinoid system.
- Non-psychoactive and found in small quantities in cannabis.
- Often used in combination with other cannabinoids for enhanced effects.

Preparation & Dosage

Common dosages range from 5 mg to 50 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

CBD, Lutein, Omega-3

Safety & Interactions

CBG appears well-tolerated in preliminary studies, with mild side effects including dry mouth, drowsiness, and increased appetite reported at higher doses. CBG may interact with cytochrome P450 enzymes, potentially affecting metabolism of medications including blood thinners and seizure medications. No specific contraindications have been established, though caution is advised for individuals taking CNS depressants due to potential additive sedative effects. Safety during pregnancy and breastfeeding has not been established, and use should be avoided without medical supervision.